DK1425037T3 - Bakteriel vaccine - Google Patents

Bakteriel vaccine

Info

Publication number
DK1425037T3
DK1425037T3 DK02755355T DK02755355T DK1425037T3 DK 1425037 T3 DK1425037 T3 DK 1425037T3 DK 02755355 T DK02755355 T DK 02755355T DK 02755355 T DK02755355 T DK 02755355T DK 1425037 T3 DK1425037 T3 DK 1425037T3
Authority
DK
Denmark
Prior art keywords
attenuated
bacteria
enterotoxins
bacterial vaccine
provides strains
Prior art date
Application number
DK02755355T
Other languages
English (en)
Inventor
Arthur Keith Turner
Judith Greenwood
Jonathan Stephens
Juliet Claire Beavis
Michael James Darsley
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1425037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1425037T3 publication Critical patent/DK1425037T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02755355T 2001-09-11 2002-09-11 Bakteriel vaccine DK1425037T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines

Publications (1)

Publication Number Publication Date
DK1425037T3 true DK1425037T3 (da) 2006-03-27

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02755355T DK1425037T3 (da) 2001-09-11 2002-09-11 Bakteriel vaccine
DK02755363.5T DK1425038T4 (da) 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02755363.5T DK1425038T4 (da) 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner

Country Status (10)

Country Link
US (4) US7943122B2 (da)
EP (2) EP1425038B2 (da)
AT (2) ATE308992T1 (da)
AU (2) AU2002321644B2 (da)
CA (2) CA2460025A1 (da)
DE (2) DE60207278T3 (da)
DK (2) DK1425037T3 (da)
ES (2) ES2256514T3 (da)
GB (1) GB0121998D0 (da)
WO (2) WO2003022306A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2005017128A2 (en) * 2003-02-26 2005-02-24 University Of Massachusetts Improved reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
US7759106B2 (en) 2004-05-19 2010-07-20 The United States Of America As Represented By The Secretary Of The Army Construction of live attenuated Shigella vaccine strains that express CFA/I antigens (CfaB and CfaE) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic E. coli
EP1855718B1 (en) * 2005-01-11 2016-10-12 The United States of America as represented by The Secretary of The Navy Donor strand complemented adhesins as immunogen against Escherichia coli.
US9328150B2 (en) 2005-01-11 2016-05-03 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
MX2009013260A (es) * 2007-07-02 2010-01-25 Crucell Sweden Ab Operon hibrido para la expresion de los antigenos del factor de colonizacion de escherichia coli enterotoxica.
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
KR101940357B1 (ko) 2011-09-12 2019-01-18 스칸디나비안 바이오파마 홀딩 에이비 세포 표면 상 ｅｔｅｃ ｃｓ６ 항원 제시의 증가 방법 및 그것의 수득가능한 산물들
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
JP2017537145A (ja) 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ カンピロバクター・ジェジュニに対する合成抗原コンストラクト
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
CA3095914A1 (en) * 2018-04-03 2019-10-10 University Of Maryland, Baltimore Enhanced shigella-enterotoxigenic e. coli multi-valent vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
ATE180280T1 (de) 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
AU5762299A (en) 1999-09-15 2001-04-17 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
PL359293A1 (en) * 2000-04-20 2004-08-23 University Of Maryland, Baltimore Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
WO2011002836A2 (en) * 2009-06-30 2011-01-06 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
US7943122B2 (en) 2011-05-17
AU2002321644B2 (en) 2008-03-13
DE60207278D1 (de) 2005-12-15
CA2460025A1 (en) 2003-03-20
DE60207278T2 (de) 2006-08-10
EP1425037B1 (en) 2005-11-09
ES2256515T5 (es) 2011-02-25
WO2003022306A3 (en) 2003-06-26
GB0121998D0 (en) 2001-10-31
WO2003022307A1 (en) 2003-03-20
US20110189225A1 (en) 2011-08-04
DE60207277T2 (de) 2006-08-03
AU2002321652B2 (en) 2008-04-10
ES2256514T3 (es) 2006-07-16
DK1425038T3 (da) 2006-03-27
US7951361B2 (en) 2011-05-31
ATE308991T1 (de) 2005-11-15
US20110200638A1 (en) 2011-08-18
DK1425038T4 (da) 2010-12-13
CA2459586A1 (en) 2003-03-20
US8318148B2 (en) 2012-11-27
US20050054075A1 (en) 2005-03-10
EP1425037A2 (en) 2004-06-09
EP1425038B2 (en) 2010-09-01
EP1425038A1 (en) 2004-06-09
DE60207278T3 (de) 2011-05-05
ATE308992T1 (de) 2005-11-15
EP1425038B1 (en) 2005-11-09
US20040253710A1 (en) 2004-12-16
WO2003022306A2 (en) 2003-03-20
ES2256515T3 (es) 2006-07-16
DE60207277D1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DE60207277D1 (de) Bakterieller impfstoff
WO2002053189A3 (en) Immunogenic complex
WO2002009643A3 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
DE60218998D1 (de) Auf Bläschen basierendes Impfstoff gegen Chlamydia
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
MA29459B1 (fr) Vaccins
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
WO2000037609A3 (en) Orally immunogenic bacterial enterotoxins expressed in transgenic plants
ATE413888T1 (de) Salmonella vakzine
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
RU99117158A (ru) Штамм бактерий pseudomonas aeruginosa 5142, используемый для изготовления вакцины против псевдомоноза пушных зверей
NO20062469L (no) Streptococcus phocae vaksine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
EE200100309A (et) Suukaudne vaktsiinikompositsioon diarröad põhjustava enterotoksigeense E. coli vastu
AU2001258579A1 (en) Virulence genes, proteins, and their use
RU2003122317A (ru) Средство, повышающее иммуногенные свойства столбнячного анатоксина
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
RU2002129867A (ru) Штамм бактерий escherichia coli км 148-продуцент протективных антигенов, используемый для иммунопрофилактики колибактериоза и холеры
RU2001132094A (ru) Штамм бактерий Escherichia coli № 28 09:K99, используемый для изготовления вакцин и диагностических препаратов